N Engl J Med: Covid-19 patients with thrombosis caused by antiphospholipid antibodies
Posted on
2 May, 2020
AURA Biopharm AS is in the preclinical phase of developing AUR-1001 as a first in class pathogenic-tailored drug for the prevention and treatment of thrombosis in patients with Antiphospholipid syndrome (APS). APS is an autoimmune disease where patients produce antiphospholipid antibodies causing thrombosis. In a recent paper in New England Journal of Medicine, 2020 Apr 8, it is reported that Covid-19 patients with positive tests for SARS-CoV-2 also had coagulopathy and antiphospholipid antibodies. This demonstrates the great medical need for new and specific treatment for APS. AUR-1001 is designed to prevent the thrombogenic effect of the antiphospholipid antibodies.